Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Research-related investments funnelled into India by U.S.-based pharmaceutical companies swelled by 10 times between 2002 and 2009 to reach $121 million, a number that will continue to grow in the years to come, according to an upcoming study by the Boston Consulting Group. The report, which was commissioned by the USA-India Chamber of Commerce (USAIC), will be released June 23 during the annual USA-India BioPharma & Healthcare Summit in Boston
You may also be interested in...
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
India And U.S. Pharma Companies Meet To Discuss Evolving Partnership Models
CAMBRIDGE, Mass. - The ever-growing engagement of the Indian pharmaceutical industry with its global counterparts - in the areas of R&D partnerships, manufacturing alliances to M&As - could be gauged from the coming together of senior level industry executives from both sides at the annual biopharma and healthcare summit sponsored by the USA-India Chamber of Commerce (USAIC) in Cambridge, Massachusetts June 23